Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4A | P47712 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.35 |
| ▸ | RBP4 | P02753 | 1/20 | 0.34 |
| ▸ | KDM5A | P29375 | 4/20 | 0.33 |
| ▸ | KDM5B | Q9UGL1 | 4/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.33 |
| ▸ | KDM4A | O75164 | 2/20 | 0.33 |
| ▸ | ASPH | Q12797 | 1/20 | 0.33 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.33 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.32 |
| ▸ | ADA | P00813 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29224232 | 0.86 | PLA2G4A (0.36) | PLA2G4AKDM4ECPB2RBP4SMYD3 | |
| SCHEMBL25235849 | 0.82 | CPB2 (0.47) | PLA2G4AKDM4ECPB2KDM5AKDM5B | |
| SCHEMBL3690823 | 0.79 | PLA2G4A (0.39) | PLA2G4AKDM4ERBP4KDM5AKDM5B | |
| SCHEMBL24035734 | 0.78 | NOTUM (0.46) | KDM4E | |
| SCHEMBL3689829 | 0.77 | PLA2G4A (0.40) | PLA2G4AKDM4ERBP4KDM5AKDM5B | |
| SCHEMBL4590582 | 0.76 | PLA2G4A (0.42) | PLA2G4AKDM4ERBP4KDM5AKDM5B | |
| SCHEMBL151394 | 0.76 | SMYD3 (0.50) | PLA2G4AKDM4ECPB2RBP4KDM5A | |
| SCHEMBL4901656 | 0.76 | PLA2G4A (0.39) | PLA2G4AKDM4ERBP4KDM5AKDM5B | |
| SCHEMBL29927335 | 0.74 | CPB2 (0.39) | PLA2G4AKDM4ECPB2SMYD3 | |
| SCHEMBL29927681 | 0.74 | CPB2 (0.39) | PLA2G4AKDM4ECPB2SMYD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11807644-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11807644-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230002403-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-01-05 | — | — | US | disclosed |
| WO-2021231474-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. (US) | 2021-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002403-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, HRAS | PLA2G4A 1123/4885KDM4E 3311/4885CPB2 2517/4885 |
| US-11807644-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, HRAS | PLA2G4A 1123/4885KDM4E 3311/4885CPB2 2517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.